AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE
Semaglutide in obesity
Abstract
Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.
Downloads
All the articles published in JAPSR are distributed under a creative commons license (CC BY-NC-SA 4.0)
Under this license, you are free to:
- Share- copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt- remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Copyright policy
The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.
Licensing policy
The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.
